Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.33 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.33 |
| ▸ | RNASEL | Q05823 | 6/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10457776 | 1.00 | FBP1 (0.36) | FBP1P2RY2P2RY4P2RY14RNASEL | |
| SCHEMBL16158825 | 1.00 | FBP1 (0.36) | FBP1P2RY2P2RY4P2RY14RNASEL | |
| SCHEMBL9964304 | 0.92 | FBP1 (0.36) | FBP1RNASEL | |
| SCHEMBL13172425 | 0.91 | FBP1 (0.36) | FBP1RNASEL | |
| SCHEMBL16996706 | 0.91 | FBP1 (0.36) | FBP1RNASEL | |
| SCHEMBL14537394 | 0.89 | FBP1 (0.34) | FBP1RNASEL | |
| SCHEMBL15304342 | 0.89 | FBP1 (0.34) | FBP1RNASEL | |
| SCHEMBL9971200 | 0.89 | FBP1 (0.34) | FBP1RNASEL | |
| SCHEMBL24211073 | 0.86 | — | — | |
| SCHEMBL9964278 | 0.86 | SMPD1 (0.34) | FBP1P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230313186-A1 | TROPHIN GENOME EDITING FOR TREATING DUCHENNE MUSCULAR DYSTROPHY (DMD) | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-10-05 | — | — | US | disclosed |
| US-8202983-B2 | Thiocarbon-protecting groups for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20090209479-A1 | THIOCARBON-PROTECTING GROUPS FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. | 2009-08-20 | — | — | US | disclosed |
| US-20090105467-A1 | Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues | MCGILL UNIVERSITY (CA) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209479-A1 | THIOCARBON-PROTECTING GROUPS FOR RNA SYNTHESIS | NSUN3, NSUN2, TRDMT1 | FBP1 1484/4885P2RY2 2665/4885P2RY4 2838/4885 |
| US-20230313186-A1 | TROPHIN GENOME EDITING FOR TREATING DUCHENNE MUSCULAR DYSTROPHY (DMD) | UTRN, MTPN, MBNL1 | FBP1 3296/4885P2RY2 4444/4885P2RY4 4633/4885 |
| US-20090105467-A1 | Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues | RNGTT, DERA, UPF1 | FBP1 8/4885P2RY2 4542/4885P2RY4 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.